Senktide (TFA)

Senktide TFA is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC50=0.5-3 nM) . Senktide TFA less potently agonizes the NK1 receptor (EC50=35 µM) . Senktide TFA is promising for research of neurological disease[1][2][3].

Product Specifications

UNSPSC

12352209

Target

Neurokinin Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

O=C(C(F)(F)F)O.O=C(N(C)[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)CC1=CC=CC=C1)[C@@H](NC([C@H](CC(O)=O)NC(CCC(O)=O)=O)=O)CC2=CC=CC=C2

Molecular Formula

C42H56F3N7O13S

Molecular Weight

955.99

References & Citations

[1]Byk G, et al. Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem. 1996 Aug 2;39 (16) :3174-8.|[2]Sarau HM, et al. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther. 1997 Jun;281 (3) :1303-11.|[3]Harrison T, et al. High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template. Bioorg Med Chem Lett. 1998 Jun 2;8 (11) :1343-8.